Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. - sprookjes - yvandenbroek - TriplyDB

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37076421

about

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma Novel agents in the treatment of multiple myeloma: a review about the future The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Immunotherapy in hematologic malignancies: past, present, and future.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.Which therapies will move to the front line for multiple myeloma?An update on the role of daratumumab in the treatment of multiple myeloma.How is patient care for multiple myeloma advancing?The safety of daratumumab for the treatment of multiple myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Monoclonal antibody therapy in multiple myeloma.Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.Is immunotherapy here to stay in multiple myeloma?Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Emerging drugs and combinations to treat multiple myeloma.Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.Is the revised International staging system for myeloma valid in a real world population?Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.Nanotherapeutics for multiple myeloma.[Multiple myeloma : What has been confirmed in therapy?]Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?Daratumumab for the Treatment of Multiple Myeloma.

P2860

Q26745919-E252A9BF-06CA-4907-A0CA-E375C5061677 Q26745924-FF3D155D-4919-409C-90DF-C45A3A428C4D Q28069789-8B4F30B5-4DD4-435A-A1AD-14340C00E0BC Q28075816-1E87BA11-927F-4871-85C2-BF760343091F Q30238893-10E17D81-5324-43D3-ACD2-B0CD2949B437 Q33434683-83A99B9A-997F-4FA9-9636-7F40D7237E3C Q33593865-645FF9BA-9CBF-4BEE-9C70-4AA8127B65E2 Q34556156-757C21BB-3F77-426A-9D83-523CB61F7335 Q36363958-220D0175-E9A2-4CB9-AE68-84F955D601D6 Q38661370-14B20995-A7A3-4C60-94AC-1BAD77B7ED27 Q38672091-7C7B7AA3-97ED-4696-8ABB-81AB42AC974E Q38711882-C4AD9FF7-964E-4FF9-AD71-586395F4B894 Q38733592-CBE4EDBC-8172-4EA0-A2D8-5CA755B98A3E Q38775700-A2832E9A-0144-4B65-8EA9-B51EAF530F2B Q38786149-F56BBB38-B91C-40D6-8A5B-9DE154BB47FB Q38793959-35D25786-E9BC-4BF8-8B41-0FB965C3CACC Q38820002-C7931548-973E-4D56-B18D-D803DA3522D3 Q38824538-E8FE6EC1-BE6A-47B8-AB6A-05F2602DCC03 Q38956372-E68964B1-391B-42E6-AE2C-C0F573973F22 Q38985014-8C966503-5D4F-4DD0-B05C-89386F22AA0C Q39084427-83C7FB9A-A4C2-42BA-A841-52EB5E13895B Q40097559-D5442908-5CB8-4F6D-A4E9-AA263550AE6F Q40163287-789592DC-481F-4058-8A08-3847116BFBC2 Q41694198-12DE27C2-8CCE-461A-8063-156466EE4348 Q46173025-D622EC12-1289-4EEE-9B96-B04CB01A1766 Q47283493-039CE72F-8986-4BD4-86FD-F94D09D7348B Q47344786-1CA10229-EC1A-44D2-8B2D-7A9DEC020003 Q47348957-DB109CAD-A33A-48A3-BBD0-8DE0AAC422C5 Q47614728-5FE24D6C-A98C-40FD-9A79-A73AF2AEF72E Q47688664-0B6EB56B-1942-4011-8EE4-7552D8F4684E Q48176748-E71CBF71-5926-43B8-9E06-4EE18351A191 Q48269862-5B319305-159B-49E3-84C2-F792D365893F Q48774591-7B4EE9A2-C112-4FC8-9B34-51B19B718FD6 Q49995833-21FD21AA-B912-4C96-A55B-F72D4F8E541C Q50211747-1AB9B866-03C8-4976-AE4C-ACA8A56F0463 Q52559684-5BCCAA10-FA00-4D68-A8B3-7FB3DA0AF7BE Q52817414-543CAAA6-D3EB-46EB-B717-E5CF6AB786D0 Q55027964-02F62EBB-F398-4C5C-8ADF-071CA8B39F0F Q55100067-498BFB3C-3B10-4282-ADF4-2565EF0A272D Q55337411-C09BAC04-BE07-4968-B75A-161BCF78778F

P2860

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37076421

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical efficacy of daratumum ...... r refractory multiple myeloma.

@en

Clinical efficacy of daratumum ...... r refractory multiple myeloma.

@nl

type

label

Clinical efficacy of daratumum ...... r refractory multiple myeloma.

@en

Clinical efficacy of daratumum ...... r refractory multiple myeloma.

@nl

prefLabel

Clinical efficacy of daratumum ...... r refractory multiple myeloma.

@en

Clinical efficacy of daratumum ...... r refractory multiple myeloma.

@nl

P1433

Q37076421-7DA21D72-89B1-45C8-ADD8-2AE6074505F1

P1476

Q37076421-B6A25BC3-39CF-4F7A-A9F5-23E5AED6623C

P2093

Q37076421-1A7DCF52-B2C7-4A34-8333-EEDADE1FD557

Q37076421-26D0F7C0-51BC-4730-BD7A-1FD101255534

Q37076421-3458867F-7369-49EF-AE29-8B02931EFD98

Q37076421-38C21668-07FB-4F80-903F-C51B323ECB77

Q37076421-437C9FAF-F9B0-4916-A5FD-209F51A96563

Q37076421-4A31B9D3-8964-411C-A592-87ED3FD9218B

Q37076421-4D2E3880-3BB5-4B73-9F54-E7725BE237D2

Q37076421-5BC60280-2B5C-4D9A-8280-7C9FA43A8404

Q37076421-6E0CD0C3-0F28-4738-94DE-0BC1E799DA9A

Q37076421-92159CCA-E156-4F48-8E10-13885000C69D

P2860

Q37076421-06A70F1B-C4B3-4017-A7BD-3195552FEC2E

Q37076421-167EDA0F-94D3-46A2-A41C-86698DBF67AB

Q37076421-1FA00787-0331-490F-A4C0-5F06F35CBDE3

Q37076421-2CBA6770-8B75-4B9D-B9AB-3BBF3B401086

Q37076421-3573611A-5AB4-47A5-AA98-DDF1DAB33D62

Q37076421-35C8631F-F3B3-4C84-9F10-CC78EAE9F630

Q37076421-3D54395C-8AF0-413B-BF84-4E8CAA6E872B

Q37076421-41C826E1-55DD-418A-8830-24D2C605CFD4

Q37076421-50932A0C-22DE-48A2-88AF-894A529E9870

Q37076421-5320AFA2-C89D-405D-B307-2D76C530E795

P304

Q37076421-CA529EC8-2D00-44C3-AB1A-E7371A60C3C6

P31

Q37076421-3C162B31-72D1-463B-8E6B-01B39E7C71EA

P356

Q37076421-7BFBE84F-A92D-461A-AB42-8F22349ED151

P407

Q37076421-669CEE4C-2F31-41E4-A0DB-941CBFE2DFFA

P433

Q37076421-37F10D56-B9E0-4433-A77E-712239E19572

P478

Q37076421-B529C608-C987-41A5-9DFB-255E35FBF640

P50

Q37076421-011871D6-11BD-409E-8DE3-F957C6187AB0

Q37076421-3D62EACB-DC32-4EB1-9EAA-B7A9273C1251

P577

Q37076421-6540EE59-1C4D-47F2-9F87-29AC2D0F3589

P698

Q37076421-4D9B86C9-9444-4371-96FD-C4572F31495A

P932

Q37076421-A0693219-794D-49C1-9CF5-CE309772675F

P356

BLOOD-2016-03-705210

P1433

P1476

Clinical efficacy of daratumum ...... r refractory multiple myeloma.

@en

P2093

A Kate Sasser

http://www.w3.org/2001/XMLSchema#string

Ajai Chari

http://www.w3.org/2001/XMLSchema#string

Amy Axel

http://www.w3.org/2001/XMLSchema#string

Andrew Belch

http://www.w3.org/2001/XMLSchema#string

Brendan M Weiss

http://www.w3.org/2001/XMLSchema#string

Clarissa M Uhlar

http://www.w3.org/2001/XMLSchema#string

Hareth Nahi

http://www.w3.org/2001/XMLSchema#string

Henk M Lokhorst

http://www.w3.org/2001/XMLSchema#string

Huaibao Feng

http://www.w3.org/2001/XMLSchema#string

Imran Khan

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Human CD38: a (r)evolutionary story of enzymes and receptors

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Pembrolizumab for the treatment of non-small-cell lung cancer

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

P304

37-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-03-705210

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Paul G Richardson

P577

2016-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27216216

http://www.w3.org/2001/XMLSchema#string

P932

4937359

http://www.w3.org/2001/XMLSchema#string